scholarly journals Elevated serum level of hepatocyte growth factor predicts development of new syndesmophytes in men with ankylosing spondylitis

Rheumatology ◽  
2020 ◽  
Author(s):  
Anna Deminger ◽  
Eva Klingberg ◽  
Merja Nurkkala ◽  
Mats Geijer ◽  
Hans Carlsten ◽  
...  
Keyword(s):  
Cohort Study ◽  
Ankylosing Spondylitis ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Radiographic Progression ◽  
Elevated Serum ◽  
Regression Analyses ◽  
Baseline Serum ◽  
Hepatocyte Growth

Abstract Objectives To study baseline serum hepatocyte growth factor (s-HGF) as a predictor of spinal radiographic progression overall and by sex and to analyse factors correlated to changes in s-HGF in patients with AS. Methods At baseline and the 5-year follow-up, s-HGF was analysed with ELISA. Spinal radiographs were graded according to modified Stoke Ankylosing Spondylitis Spinal Score. Radiographic progression was defined as ≥2 modified Stoke Ankylosing Spondylitis Spinal Score units/5 years or development of ≥1 syndesmophyte. Logistic regression analyses were used. Results Of 204 baseline participants, 163 (80%) completed all examinations at the 5-year follow-up (54% men). Baseline s-HGF was significantly higher in men who developed ≥1 syndesmophyte compared with non-progressors, median (interquartile range) baseline s-HGF 1551 (1449–1898) vs 1436 (1200–1569) pg/ml, P = 0.003. The calculated optimal cut-off point for baseline s-HGF ≥1520 pg/ml showed a sensitivity of 70%, a specificity of 69% and univariate odds radio (95% CI) of 5.25 (1.69, 14.10) as predictor of development of ≥1 new syndesmophyte in men. Baseline s-HGF ≥1520 pg/ml remained significantly associated with development of ≥1 new syndesmophyte in men in an analysis adjusted for the baseline variables age, smoking, presence of syndesmophytes and CRP, odds radio 3.97 (1.36, 11.60). In women, no association with HGF and radiographic progression was found. Changes in s-HGF were positively correlated with changes in ESR and CRP. Conclusion In this prospective cohort study elevated s-HGF was shown to be associated with development of new syndesmophytes in men with AS.

Induction of liver growth in normal mice by infusion of hepatocyte growth factor/scatter factor

1995 ◽  
Vol 268 (2) ◽  
pp. G380-G386 ◽  
Author(s):  
F. Roos ◽  
A. M. Ryan ◽  
S. M. Chamow ◽  
G. L. Bennett ◽  
R. H. Schwall
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Dextran Sulfate ◽  
Plasma Concentrations ◽  
Elevated Serum ◽  
Serum Levels ◽  
Serum Biochemistry ◽  
Scatter Factor ◽  
Liver Growth ◽  
Hepatocyte Growth

Hepatocyte growth factor/scatter factor (HGF/SF) is a potent stimulator of DNA synthesis in a variety of epithelial cells, including hepatocytes, and has been implicated in liver regeneration. We show here that combining dextran sulfate with HGF/SF markedly increases the plasma concentrations of HGF/SF that are achieved during intraperitoneal infusion. Three days of administration of HGF/SF by this mechanism caused a dose-dependent increase in liver wet weight. Mitotic figures were rarely observed in control livers but were abundant in livers exposed to HGF/SF, and liver DNA content was elevated. Serum levels of triglycerides, cholesterol, total protein, and albumin were also dose dependently increased, whereas alkaline phosphatase was reduced. From these data we conclude 1) that combining HGF/SF with dextran sulfate provides a novel method for delivering HGF/SF in a continuous manner, 2) that HGF/SF can induce liver growth in an intact animal, and 3) that HGF/SF-induced liver enlargement is associated with changes in serum biochemistry.

Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia

2009 ◽  
Vol 62 (2) ◽  
pp. 129-134 ◽  
Author(s):  
H. Hjorth-Hansen ◽  
C. Seidel ◽  
J. Lamvik ◽  
M. Börset ◽  
A. Sundan ◽  
...  
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Elevated Serum ◽  
Serum Concentrations ◽  
Myelocytic Leukaemia ◽  
Acute Myelocytic Leukaemia ◽  
Hepatocyte Growth

HIGH LEVEL OF THE SERUM HEPATOCYTE GROWTH FACTOR PREDICTS THE DEVELOPMENT OF METABOLIC SYNDROME:THE TANUSHIMARU COHORT STUDY

2011 ◽  
Vol 29 ◽  
pp. e149
Author(s):  
E. Tsukagawa ◽  
H. Adachi ◽  
Y. Hirai ◽  
M. Enomoto ◽  
A. Fukami ◽  
...  
Keyword(s):  
Cohort Study ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
High Level ◽  
Hepatocyte Growth

Diagnostic validity of hepatocyte growth factor as marker for rejection in the follow-up of patients after heart transplantation

2005 ◽  
Vol 24 (4) ◽  
pp. 411-415 ◽  
Author(s):  
Krystyna Żwirska-Korczala ◽  
Michał Zakliczyński ◽  
Agnieszka Berdowska ◽  
Marian Zembala ◽  
Jerzy Jochem ◽  
...  
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Heart Transplantation ◽  
Diagnostic Validity ◽  
Hepatocyte Growth

scholarly journals Improvement of physical activity was significantly reduced serum hepatocyte growth factor levels in a general population: 10-year prospective study

2021 ◽  
Author(s):  
Akiko Sakaue ◽  
Hisashi Adachi ◽  
Mika Enomoto ◽  
Ako Fukami ◽  
Yume Nohara ◽  
...  
Keyword(s):  
Physical Activity ◽  
Growth Factor ◽  
General Population ◽  
Hepatocyte Growth Factor ◽  
Community Dwelling ◽  
Inverse Association ◽  
The Metabolic Syndrome ◽  
Hepatocyte Growth ◽  
Age And Sex

Abstract Background: We have previously reported that hepatocyte growth factor (HGF) levels were significantly associated with insulin resistance or components of the metabolic syndrome. However, it has been unknown how physical activity (PA) affects HGF levels after a long-term follow-up.Aims: Our aim was to clarify the association between PA changes and HGF levels /cerebro-cardiovascular disease (CVD) development during 10 years follow-up period in a community-dwelling Japanese general population.Methods: Of 1,320 subjects who received a health check-up examination in Tanushimaru town in 1999, 903 subjects (341 males and 562 females) were enrolled, who received the examination both in 1999 and 2009. We evaluated their PA levels by Baecke questionnaire in 1999 and evaluated their PA levels by a simple questionnaire in 2009. We measured the serum HGF levels by ELISA method in 1999 and 2009. We divided into four physical activity groups such as stable low PA, increased PA, decreased PA, and stable high PA. Using these questionnaires, we compared their PA and HGF levels in 10 years.Results: A significant inverse association was found between PA changes and serum HGF levels in 10 years after adjustment for age and sex. The serum HGF levels of increased PA group were significantly lower than stable low PA (p=0.038), and the former group showed the reduced CVD development compared to the latter group after adjustment for age and sex (p=0.012).Conclusions: Our data demonstrated that improvement of PA levels was associated with reduced HGF levels and CVD development.

scholarly journals Association of Circulating Hepatocyte Growth Factor and Risk of Incident Peripheral Artery Disease: The Multi-Ethnic Study of Atherosclerosis

Angiology ◽  
2020 ◽  
Vol 71 (6) ◽  
pp. 544-551
Author(s):  
Parveen K. Garg ◽  
Petra Buzkova ◽  
Christina L. Wassell ◽  
Matthew Allison ◽  
Michael Criqui ◽  
...  
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Ankle Brachial Index ◽  
Arterial Disease ◽  
Ethnic Study ◽  
Increased Risk ◽  
Artery Disease ◽  
Peripheral Arterial ◽  
Hepatocyte Growth

Higher levels of hepatocyte growth factor (HGF) have been associated with the presence of peripheral arterial disease (PAD), but prospective associations are unknown. We examined the association of circulating HGF levels with incident PAD. Between 2000 and 2002, HGF was measured in 6742 Multi-Ethnic Study of Atherosclerosis participants without PAD. Incident clinical PAD, adjudicated on the basis of a positive history for the presence of disease-related symptoms or treatment, was ascertained through 2015. Incident low ankle-brachial index (ABI), defined as an ABI < 0.9 and a decline of ≥ 0.15, was assessed among 5736 individuals who had an ABI > 0.9 at baseline and ≥1 follow-up ABI measurement 3 to 10 years later. There were 116 clinical PAD and 197 low ABI events that occurred over a median follow-up of 14 and 9 years, respectively. After adjustment for demographic and clinical variables, a standard deviation increment of HGF (303 ng/L) was associated with an increased risk of clinical PAD (hazard ratio: 1.21; 95% confidence interval [CI]: 1.05-1.39) but not a low ABI (rate ratio: 1.03; 95% CI: 0.85-1.25). In conclusion, higher HGF levels were modestly associated with an increased risk of developing clinical PAD.

scholarly journals Elevated Serum Concentrations of Hepatocyte Growth Factor in Patients With Multiple Myeloma

Blood ◽  
1998 ◽  
Vol 91 (3) ◽  
pp. 806-812 ◽  
Author(s):  
Carina Seidel ◽  
Magne Børset ◽  
Ingemar Turesson ◽  
Niels Abildgaard ◽  
Anders Sundan ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Growth Factor ◽  
Prognostic Factor ◽  
Hepatocyte Growth Factor ◽  
Cox Regression ◽  
Elevated Serum ◽  
Cox Regression Analysis ◽  
Β2 Microglobulin ◽  
Serial Samples ◽  
Hepatocyte Growth

Abstract Serum from 398 myeloma patients at diagnosis and serial samples from 29 patients were analysed for hepatocyte growth factor (HGF). HGF was elevated at diagnosis in 43% of myeloma patients compared with healthy controls (median 1.00 ng/mL and 0.44 ng/mL, respectively;P < .00001). In the group with elevated HGF levels 46% of the patients reached plateau phase, as compared with 60% of the patients with low HGF levels (P = .005), and the median survival time was 21 and 32 months, respectively (P = .002). In a univariate Cox regression analysis, HGF was a significant predictor of mortality (P = .02). In the subgroup of patients with β2-microglobulin levels less than or equal to 6 mg/L, high versus low HGF was a prognostic factor when a multivariate Cox regression analysis was performed. In serial samples HGF was higher at the time of diagnosis and relapse (median 0.57 ng/mL and 0.52 ng/mL, respectively; P = .0018) than at response (median 0.24 ng/mL, P = .008). We conclude that HGF may be a useful follow-up parameter in myeloma patients. Measurement of HGF may identify a group of patients with poor response to melphalan-prednisone treatment and short survival. HGF was a prognostic factor in patients with high levels of β2-microglobulin.

Sign in / Sign up

Export Citation Format

Share Document